CNSP
CNS Pharmaceuticals Inc
NASDAQ: CNSP · HEALTHCARE · BIOTECHNOLOGY
$6.12
-5.30% today
Updated 2026-06-05
Market cap
$7.72M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-24.12
Dividend yield
—
52W range
$2 – $13
Volume
1.8M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C2.0
Quality
F3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-21.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$10.00
+63.40%
12-Month target
$5,277.00
+86125.49%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -21.12 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-4.65M
- Debt/equity 3.29x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-15.27M | $-18.85M | $-14.86M | $-15.85M | $-4.94M |
| EPS | — | — | — | — | $-24.12 |
| Free cash flow | $-10.56M | $-14.14M | $-17.12M | $-13.83M | $-4.65M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
CNS Pharmaceuticals Inc trades at $6.12. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -21.12, it sits in the distress.
Frequently asked questions
What is CNS Pharmaceuticals Inc's stock price?
CNS Pharmaceuticals Inc (CNSP) trades at $6.12.
Is CNS Pharmaceuticals Inc overvalued?
CNS Pharmaceuticals Inc carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of CNS Pharmaceuticals Inc (CNSP)?
The 12-month analyst consensus target is $10.00, about 63.4% above the current $6.12. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
CNS Pharmaceuticals Inc's Altman Z-Score is -21.12, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-298.60%
Beta0.54
50D MA$3.86
200D MA$5.68
Shares out0.00B
Float0.00B
Short ratio—
Avg volume1.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—